Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment

Journal of Clinical Pharmacology

Volumn 49, Issue 4, 2009, Pages 465-476

  Marbury, Thomas ^a   Dowell, James A ^b,c   Seltzer, Elyse ^b   Buckwalter, Mary ^b  

^a ORLANDO CLINICAL RESEARCH CENTER   (United States)

^b PFIZER INC   (United States)

^c Ception Therapeutics   (United States)

Author keywords

Dalbavancin; Hepatic impairment; Pharmacokinetics; Renal impairment

Indexed keywords

CREATININE; DALBAVANCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; RASH; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AUDIOMETRY; FEMALE; HEARING; HEPATIC INSUFFICIENCY; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; TEICOPLANIN; TIME FACTORS;

EID: 63849324196     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008330162     Document Type: Article

References (32)

1. Candiani G., Abbondi M., Borgonovi M., Romano G., Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semisynthetic glycopeptide antibiotic. J Antimicrob Chemother. 1999; 44: 179-192.
2. Streit JM, Fritsche TR, Sader HS, Jones RN Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004; 48: 137-143.
3. Lin G., Credito K., Ednie LM, Appelbaum PC Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother. 2005; 49: 770-772.
4. Seltzer E., Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003; 37: 1298-1303.
5. Jauregui LE, Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005; 41: 1407-1415.
6. Cavaleri M., Riva S., Valagussa A., et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother. 2005; 55 (suppl 2). ii31 - ii35.
7. Leighton A., Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004; 48: 940-945.
8. Buckwalter M., Dowell JA Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005; 45: 1279-1287.
9. Dorr MB, Jabes D., Cavaleri M., et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005; 55 (suppl 2). ii25 - ii30.
10. Dowell JA, Gottlieb AB, Van Saders C., et al. The pharmacokinetics and renal excretion of dalbavancin in healthy subjects. Poster presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA.
11. Stogniew M., Pu F., Dowell JA, Henkel T. Pharmacokinetic attributes of dalbavancin: well distributed and completely eliminated with dual routes of elimination. Clin Microbiol Infect. 2003; 9 (suppl 1). 291.
12. Wilson AP Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000; 39: 167-183.
13. Brown N., Ho DHW, Fong K-LL, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother. 1983; 23: 603-609.
14. Food and Drug Administration. Guidance for Industry: Pharmacokinetics in Patients With Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Rockville, MD: Office of Training and Communication Division of Drug Information, Center for Drug Evaluation and Research; May 1998.
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60: 646-649.
16. Food and Drug Administration. Guidance for Industry: Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Rockville, MD: Office of Training and Communication Division of Drug Information, Center for Drug Evaluation and Research; May 2003.
17. Fausti SA, Henry JA, Helt WJ, et al. An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear. 1999; 20: 497-505.
18. White RJ, Brown GL, Cavaleri M., Romano G. V-Glycopeptide: phase 1 single and multiple-dose placebo controlled intravenous safety, pharmacokinetic, and pharmacodynamic study in healthy subjects. Presented at: 44th Interscience Conference of Antimicrobial Agents and Chemotherapy; October 30 to November 2, 2004; Washington, DC. Abstract 682.
19. Raad I., Darouiche R., Vazquez J., et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005; 40: 374-380.
20. Meyer B., Traunmuller F., Hamwi A., et al. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-h used highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage. Int J Clin Pharmacol Ther. 2004; 42: 556-560.
21. Ruano R., Martin-Reyes G., Munoz I., et al. Monitoring of vancomycin plasma levels in patients undergoing hemodialysis. Farm Hosp. 2005; 29: 354-358.
22. Lam YW, Kapusnik-Uner JE, Sachdeva M., Hackbarth C., Gambertoglio JG, Sande MA The pharmacokinetics of teicoplanin in varying degrees of renal function. Clin Pharmacol Ther. 1990; 47: 655-661.
23. Bonati M., Traina GL, Villa G., et al. Teicoplanin pharmacokinetics in patients with chronic renal failure. Clin Pharmacokinet. 1987; 12: 292-301.
24. Harada H., Miyagawa S., Kawasaki S., et al. Study of the pharmacokinetics of vancomycin in patients with impaired liver function. J Infect Chemother. 1999; 5: 104-107.
25. Domart Y., Pierre C., Clair B., Garaud JJ, Regnier B., Gibert C. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment. Antimicrob Agents Chemother. 1987; 31: 1600-1604.
26. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity: a review. Med Toxicol Adverse Drug Exp. 1988; 3: 376-386.
27. Pea F., Brollo L., Viale P., Pavan F., Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother. 2003; 51: 971-975.
28. Darley ES, MacGowan AP The use of therapeutic drug monitoring of teicoplanin in the UK. Clin Microbiol Infect. 2004; 10: 62-69.
29. Barriere S., Shaw JP, Seroogy J., Spencer E., Kitt M. Pharmacokinetics (PK) and safety of a new antibacterial, TD-6424 (TD), in healthy subjects. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract A-20.
30. Duchin K., Shaw J., Spencer E., Seroogy J., Barriere S., Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Abstract P1028.
31. Knechtel SA, Jacobs C., Klepser ME Telavancin: a novel lipoglycopeptide antibiotic with dual mechanisms of action. Formulary. 2007; 42: 545-557.
32. Wong SL, Shaw JP, Bereriere S., Kitt M., Goldberg M. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Abstract A-1951.